SAM
VRDN icon

Seelaus Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Seelaus Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,145
Closed -$13K – 206
2020
Q3 		$13K Hold
1,145
– – 0.01% 163
2020
Q2 		$19K Buy
+1,145
New +$13K 0.02% 145
2019
Q4 		– Sell
-1,145
Closed -$13K – 178
2019
Q3 		$13K Buy
+1,145
New +$25.3K 0.01% 162

Other funds holding VRDN

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Seelaus Asset Management's VRDN Position: Q4 2020 in Review

Seelaus Asset Management sold out of Viridian Therapeutics (VRDN) in Q4 2020, closing a stake of 1,145 shares — an estimated $13K sold.

Seelaus Asset Management first reported a position in VRDN in Q3 2019 and held it in 3 quarters. The position peaked at $19K in Q2 2020. 22 funds tracked by Wall St. Rank hold VRDN as of Q4 2020.

  • Seelaus Asset Management reported no remaining Viridian Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Seelaus Asset Management sold 1,145 Viridian Therapeutics shares in Q4 2020, an estimated $13K.
  • Seelaus Asset Management first reported a position in Viridian Therapeutics in Q3 2019 and held it in 3 quarters.
  • Seelaus Asset Management's Viridian Therapeutics position peaked at $19K in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2020.

Based on Seelaus Asset Management's 13F filing for Q4 2020, filed 8 Feb 2021.